New investigational drug holds promise for combatting deadly mucormycosis infections

With very few treatment options available to fight deadly mucormycosis infections, a new Los Angeles Biomedical Research Institute (LA BioMed) study holds hope for adding to the arsenal of therapies physicians have to combat an increasingly common infection afflicting people with weakened immune systems.

An LA BioMed research team reported in an online, ahead-of-print study in the Antimicrobial Agents and Chemotherapy journal that the investigational drug isavuconazole was as effective in reducing mucormycosis infections in disease models as the most widely used treatment currently on the market, high-dose liposomal amphotericin B. Isavuconazole is an investigational once-daily intravenous and oral broad-spectrum antifungal for the potential treatment of severe invasive and life-threatening . It is currently in phase 3 of clinical development.

"Expanding the options for fighting these is especially important for patients who can't tolerate current treatments or whose infections may not respond to the antifungals on the market today," said Ashraf S. Ibrahim, PhD, an LA BioMed lead researcher and the corresponding author for the study. "With such a limited number of treatments available, developing new therapies is critical to increasing the number of people who survive these extremely lethal infections. "

Patients with , hyperglycemia, acidosis (diabetic ketoacidosis or other forms of acidosis), malnutrition, or trauma patients are at increased risk of mucormycosis infection. Despite the current treatments and surgeries available to treat mucormycosis, more than half of patients with the infections die.

"Clearly, new strategies for preventing and treating mucormycosis are urgently needed," the researchers concluded.

They examined the most common form of this deadly infection, mucormycosis due to Rhizopus delemar, and concluded that their results support the further development of isavuconazole.

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Kidney-brain connection may help drive chronic kidney disease

11 hours ago

In addition to affecting blood pressure, high-salt intake can promote kidney function decline in patients with chronic kidney disease. A study appearing in an upcoming issue of the Journal of the American Society of Nephrology (J ...

Flu's grip on U.S. starting to weaken: CDC

11 hours ago

(HealthDay)—After a rough start to the flu season, the number of infections seems to have peaked and is even starting to decline in many parts of the nation, federal health officials reported Thursday.

Litchi fruit suspected in mystery illness in India

11 hours ago

A mysterious and sometimes fatal brain disease that has afflicted children in northeastern India for years could be linked to a toxic substance in litchi fruits, US researchers said Thursday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.